Salute e Benessere

Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study…

DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present detailed results from its Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1) at World Sleep Congress, taking place Sept. 5-10, 2025 in Singapore, and in an investor webcast presentation hosted by the company. Alixorexton, formerly referred to as ALKS 2680, is the company's novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in phase 2…
PR Newswire
25/08/2025

OrganOx achieves one of the UK's largest medtech exit to date, generating record…

The deal represents one of the largest exits of a UK medtech company, at $1.5bn (the total transaction value is approximately $1.5bn). It also marks BGF's largest-ever return, generating £175m of proceeds. The deal has driven a 10x money multiple (MM) exit on BGF's initial investment and an overall IRR in the region of 69 percent. The deal represents one of the largest exits of a UK medtech company, at$1.5bn(the total transaction value is approximately$1.5bn ). It also marks BGF's...
PR Newswire
25/08/2025

Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D…

Mark Kupersmith, M.D. appointed as Chief Medical Advisor, Neuro-Ophthalmology, following positive Phase 2 ACUITY trial results with Privosegtor (OCS-05) in acute optic neuritis and initiation of multiple programs in neuro-ophthalmologySebastian Wolf, M.D., Ph.D. appointed as Chief Medical Advisor, Ophthalmology, following the material advancement in retina programs with recent enrollment completion of Phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema and positive Phase...
Nasdaq GlobeNewswire
25/08/2025

Digital Health Market is Estimated to Reach USD 449.19 Billion by 2032 |…

Get a Free Sample Report - https://www.skyquestt.com/sample-request/digital-health-market Get a Free Sample Report-https://www.skyquestt.com/sample-request/digital-health-market Digital Health Market Key Growth Drivers The digital health market has experienced significant growth, owing to government initiatives, promoting digital healthcare infrastructure, and regulatory support are crucial growth factors. Many countries are investing in e-health policies, telemedicine...
PR Newswire
25/08/2025

Lundbeck to present new data on bexicaserin at upcoming congress, highlighting…

"Patients with DEEs represent a challenging group of rare epilepsies, with few effective approved treatment options," said Johan Luthman, EVP and Head of Research and Development at Lundbeck. "As we are now in phase 3 trials with bexicaserin, we are optimistic about its potential. The clinical data so far suggests broad and durable anti-seizure activity across DEEs, and new preclinical data suggests modulation of the risk of sudden unexpected death in epilepsy (SUDEP). This marks…
PR Newswire
25/08/2025

Leqembi® (lecanemab) launched in the EU today

Alzheimer's disease is a progressive, relentless disease with Aβ and tau as hallmarks. It progresses in stages that increase in severity over time, and each stage of the disease presents different challenges for those living with the disease and their care partners. There is a significant unmet need for new treatment options that slow the progression of Alzheimer's disease from its early stage and reduce the overall burden on people affected by Alzheimer's disease and society. Only Leqembi…
PR Newswire
25/08/2025

Antengene Announces 2025 Interim Results with Encouraging Clinical Data and…

Forward-looking Statements: Forward-looking Statements: For details on forward-looking statements, please refer to our full Interim Results press release on the Company's website:https://www.antengene.com/newsinfo/442 For more information, please contact: Investor Contacts: Donald LungE-mail:[email protected] Mobile: +86 18420672158 PR Contacts:Peter QianE-mail:[email protected] Mobile: +86 13062747000 Logo -https://mma.prnewswire...
PR Newswire
25/08/2025

Austria and Germany to become the first markets in the European Union (EU) to…

TOKYO and CAMBRIDGE, Mass., Aug.25, 2025(GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the anti-amyloid beta (Aβ) monoclonal antibody “LEQEMBI ® ” has been launched in Austria on August 25, 2025 and will be launched in Germany on September 1, 2025. LEQEMBI received the European Commission (EC) approval in April...
Nasdaq GlobeNewswire
25/08/2025

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine…

Saint Herblain (France), August 25, 2025–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ ®in the United States. The suspension...
Nasdaq GlobeNewswire
25/08/2025

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic…

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General MeetingNew Board Structure Reflects Balanced and Proportionate Shareholder RepresentationNew Governance to Drive Strategic Roadmaps for Tedopi® and LusvertikimabNantes, August 25, 2025, 7:00 a.m. CET -OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the convening of its Annual General Shareholders’ Meeting, to be held on September 30, 2025,...
Nasdaq GlobeNewswire
25/08/2025

Levoit Sprout Air Purifier Launches in UAE: Protection for Nesting Mothers…

Building on the success of Levoit's Core Series, the Sprout addresses urgent indoor air quality concerns in the UAE, particularly for families with young children. Its development incorporated extensive consumer feedback, resulting in a purpose-built solution for nurseries and family spaces. Building on the success of Levoit's Core Series, the Sprout addresses urgent indoor air quality concerns in the UAE, particularly for families with young children. Its development incorporated extensive...
PR Newswire
25/08/2025

Cambrex Expands Peptide Manufacturing Capabilities in Waltham, Massachusetts

"We designed this facility with a three-step strategy in mind for the development of peptide drug candidates," said Dr. Eric Fang, General Manager at Snapdragon Chemistry. "We start with automated SPPS technology for proof-of-concept. In parallel, we optimize the process using LPPS technology to accelerate development and reduce manufacturing cost. We can then transfer the process to our large manufacturing facilities, such as Charles City, Iowa, to produce materials in…
PR Newswire
25/08/2025

Terumo to acquire OrganOx Limited, a leading innovator in organ preservation…

- Expanding opportunities for organ transplantation worldwide and contributing to the advancement of transplant medicine -OXFORD, United Kingdom and MADISON, N.J., Aug.24, 2025(GLOBE NEWSWIRE) -- Terumo Corporation (TSE: 4543, “Terumo”) today announced that Terumo has entered into a definitive agreement dated August 23, 2025, with OrganOx Limited (“OrganOx” or the “Company”), a leading innovator in organ preservation devices, and its shareholders to acquire all outstanding shares of...
Nasdaq GlobeNewswire
25/08/2025

Targeted Protein Degradation Market worth $9.85 billion by 2035 with 35.4% CAGR…

Browse in-depth TOC on "Targeted Protein Degradation Market" Browse in-depth TOC on "Targeted Protein Degradation Market" 380 - Tables60 - Figures402 - Pages By formulation,the global targeted protein degradation market is segmented by formulation into two main categories: oral and injections. In 2024, the oral formulations segment holds the highest share in the formulation landscape of the novel TPD market, driven by its favorable pharmacokinetics, patient compliance,...
PR Newswire
23/08/2025

Innocan's Findings to be Showcased in Scientific Poster Reception at PAINWeek…

To arrange a meeting with Innocan during PAINWeek please e-mail: [email protected] To arrange a meeting with Innocan during PAINWeek please e-mail:[email protected] PAINWeek is a prestigious event that brings together leading clinicians, researchers, and educators in the field of pain medicine, offering a unique platform to showcase innovative research and best practices. The narrative review, selected through a competitive peer-review process, provides important insights into...
PR Newswire
22/08/2025

Anesthesia and Respiratory Devices Market to Hit $74.8 Billion by 2030

This report offers a comprehensive analysis of the global market for anesthesia and respiratory devices. It segments the market by product types and regions, including North America, Europe, Asia-Pacific, South America, and the Middle East and Africa, with a focus on key countries. The study explores market drivers, challenges, the vendor landscapes, ESG developments, regulatory frameworks, and emerging technologies. It concludes with a competitive analysis, ranking major companies and providing…
PR Newswire
22/08/2025

Empty Capsules Market worth $4.19 billion by 2030 with 5.6% CAGR |…

Browse in-depth TOC on "Empty Capsules Market"356 - Tables48 - Figures459 - Pages Browse in-depth TOC on "Empty Capsules Market" 356 - Tables 48 - Figures 459 - Pages By functionality,the empty capsules market is categorized into immediate-release capsules, sustained-release capsules, delayed-release capsules, and modified-release capsules. The immediate-release capsules segment is the largest in the empty capsules market. These capsules are typically used for medications…
PR Newswire
22/08/2025

Trading by management and close relations of management

Please read the announcement in PDF Attachment 2025_40_Trading_By_Management
Nasdaq GlobeNewswire
22/08/2025

3D Printed Drugs Market Size to Reach US$ 522.73 Million by 2033 - Exclusive…

Emerging players and established players are investing in novel 3D printing platforms and materials to enhance drug design and manufacturing efficiency. Government and private sector funding, alongside growing demand for personalized medicine, are accelerating adoption, highlighting a multifaceted approach to transforming drug production and patient care. Emerging players and established players are investing in novel 3D printing platforms and materials to enhance drug design and...
PR Newswire
22/08/2025

Biosimilars Market to Surpass US$ 171.79 Billion by 2033 - Exclusive Report by…

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response) - https://datamintelligence.com/download-sample/biosimilars-market Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response) - https://datamintelligence.com/download-sample/biosimilars-market TheAsia-Pacific(APAC) region, especiallyJapan, has emerged as a leading market for biosimilars, driven by strong government support, favorable reimbursement policies, and...
PR Newswire
22/08/2025

Medical Device Contract Manufacturing Market worth $140.84 billion by 2030 with…

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170622851 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170622851 Browse in-depth TOC on "Medical Device Contract Manufacturing Market" 440 - Tables 68 - Figures 429 - Pages By IVD device type,within the category of In Vitro Diagnostic (IVD) devices, IVD consumables are projected to experience the highest compound annual growth rate (CAGR) from 2024 to 2030...
PR Newswire
22/08/2025

Walking Aids Market to Register 7.2% CAGR to Reach US$29.31 Billion by 2031 |…

Growth of the walking aids market is driven by several key factors, such as the aging worldwide population; heightened prevalence of musculoskeletal conditions like arthritis and Parkinson's; greater recognition of mobility aid alternatives; and product design innovations—such as intelligent sensors, ergonomic engineering, lightweight and foldable materials. Regionally, Asia-Pacific is projected to grow rapidly, driven by its fast-growing elderly population and strengthened health…
PR Newswire
22/08/2025

Epigenetics Market is expected to generate a revenue of USD 3.70 Billion by…

The Epigenetics Market is witnessing strong expansion as research in oncology, neurology, and personalized medicine surges. With breakthroughs in biomarkers and diagnostics, epigenetic tools are reshaping drug development, though cost and expertise remain key challenges to mainstream adoption. The Epigenetics Market is witnessing strong expansion as research in oncology, neurology, and personalized medicine surges. With breakthroughs in biomarkers and diagnostics, epigenetic tools are…
PR Newswire
22/08/2025

Flaggemelding

Hawkeye Invest AS, et selskap som kontrolleres av Øystein Barmen, har i dag solgt 2 000 000 aksjer i PCI Biotech Holding ASA. Etter handelen eier Hawkeye Invest AS ingen aksjer i PCI Biotech Holding ASA.
Nasdaq GlobeNewswire
22/08/2025
Altri  Comunicati